Dapagliflozin for inflammation and anemia in diabetic kidney disease
Treatments studied
Part of Hormones & metabolism, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests a medication called dapagliflozin to see if it can reduce inflammation and improve red blood cell and iron levels in people with type 2 diabetes and chronic kidney disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are older than 18 years.
- You have been diagnosed with type 2 diabetes.
- Your kidney function (eGFR) is between 20 and 80.
- You have a urine albumin-to-creatinine ratio between 30 and 3500.
- Your HbA1c (average blood sugar) is between 7% and 11%.
- You do not have type 1 diabetes or another kidney disease, and your hemoglobin is not below 9.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether dapagliflozin can improve heart structure and function in people with chronic kidney disease (CKD). Dapagliflozin is a kidney-heart medicine that may affect how the heart changes over time, measured by heart scans.
This trial tests whether taking dapagliflozin (a drug often used for diabetes and heart health) can help improve kidney structure and blood flow in people who received a kidney transplant at least 9 months ago. It may benefit those whose kidney function is stable, regardless of whether they have diabetes.
This trial tests whether a medication called dapagliflozin can help improve anemia in people with chronic kidney disease. If you have moderate to severe kidney disease and low red blood cell counts despite taking standard anemia treatment, this study may explore a new option.
This trial tests whether a diabetes drug called dapagliflozin can help people on peritoneal dialysis keep their remaining kidney function longer. It is for patients who started dialysis recently and still make urine.
This trial tests whether a diabetes medicine called dapagliflozin can help improve anemia (low red blood cell count) in people with lower-risk myelodysplastic syndromes. Myelodysplastic syndromes are a group of blood disorders where the bone marrow doesn't make enough healthy blood cells. The study aims to see if this drug can help you feel better by boosting your blood counts.
This trial tests whether a diabetes medicine called dapagliflozin can help protect kidney function in people with AL amyloidosis. You must live in Michigan and have stable or improving protein in your urine.
Hear when a new Chronic Kidney Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.